Diabetic retinopathy is a medical condition which damages retina (present at the back of eye) and leads to blindness if untreated or undiagnosed. The degree of treatment of diabetic retinopathy varies according to various stages of the disease and is mainly prioritized to curb the disease at its initial stage.
The global diabetic retinopathy drug market is anticipated to bolster at a robust growth rate to reach USD 705 Million by 2021. Geographically, the global diabetic retinopathy drug market is segmented into North America, Latin America, Western and Eastern Europe, Asia-Pacific, Middle East and North Africa (MENA) and Rest of World.
Regionally, North America dominates the global diabetic retinopathy drug market. The region also accounted for 36.0% of total diabetic retinopathy market in 2015. Diabetic retinopathy drug market in the region is expected to escalate and get sparked by huge government spending on healthcare industry in coming 5-6 years.
Europe is the second largest diabetic retinopathy drug market behind North America. The market in the region is anticipated to propagate by increasing number of obese people, who are more prone to diabetes, in some of the major European countries including the U.K., Germany, Spain, France, Italy and Spain. Asia-Pacific diabetic retinopathy drug market is believed to have the highest growth over the covered forecast period. Rapid expansion of diabetic population, increasing per capita income and major investments in health infrastructure are some of the key factors which are expected to propel the diabetic retinopathy drug market in countries such as India and China over next 4-5 years.Japan diabetic retinopathy drug market is also anticipated to witness a burgeoned expansion fuelled by rapid growth of geriatric population in the country. CLICK TO DOWNLOAD FREE SAMPLE REPORT
The global diabetic retinopathy drugs market is segmented based on type of drugs into intraocular steroid injection, Avastin, Lucentis and Anti-Vascular Endothelial Growth Factor (VEGF) drug.
On the basis of end-users, the global diabetic retinopathy drug market is divided as ophthalmic clinics, hospitals, ambulatory surgical centers and others.
The study further analysis the Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Sweden, Finland), Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa).
Rapidly expanding diabetic population coupled with increasing awareness of people regarding diabetic retinopathy is expected to drive the growth of global diabetic retinopathy drug market in coming 4-5 years. In addition to that, rising medical procedures due to high penetration of medical insurance and rising government initiatives for prevention of diabetes related risks is also believed to garner the growth of global retinopathy drug market in future.
However, lack of trained ophthalmologist and stringent government regulations for approval of diabetic retinopathy drugs is anticipated to restrain the growth of global diabetic retinopathy drugs market over the forecast period i.e. 2015-2021.
Global diabetic retinopathy market is very competitive and includes some of the top players such as Roche, Moore Drug Company, Regeneron Pharmaceuticals Inc., Bayer Healthcare, ThromboGenics, Actavis PLC, Actavis PLC, Sirnaomics Incorporation, Parexel International Corp., etc.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization